Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, China.
Minerva Anestesiol. 2020 Oct;86(10):1065-1078. doi: 10.23736/S0375-9393.20.14304-9. Epub 2020 Mar 11.
It remains unclear whether intraoperative use of volatile anesthetics has a positive effect on postoperative clinical outcomes in patients undergoing coronary artery bypass grafting (CABG). Therefore, we aimed to systematically analyze the long- and short-term mortality rates and the clinical outcomes of volatile anesthesia compared to those of total intravenous anesthesia (TIVA) in patients undergoing CABG.
We queried the MEDLINE, Embase, and CENTRAL databases from inception to October 2019 for relevant randomized clinical trials (RCTs) on the intraoperative use of volatile anesthetics in patients undergoing CABG.
We pooled and analyzed 36 eligible RCTs with 10,308 patients and found that there was no significant difference in the long- and short-term mortality rate between the use of volatile anesthesia and TIVA during CABG. 30-day mortality, volatile group (39/2,824, 1.4%) vs. TIVA group (35/2,786, 1.3%), RR=1.11, 95% CI [0.70, 1.74], P value for effect =0.66, I=0%, moderate-certainty evidence; One-year mortality, volatile group (77/2,749, 2.8%) vs. TIVA group (78/2,731, 2.9%), RR=0.98, 95% CI [0.72, 1.34], P value for effect =0.90, I=0%, moderate-certainty evidence. Mechanical ventilation time was reduced in volatile group (MD -0.65, 95% CI [-1.07, -0.24], P value for effect =0.002, I=26%).
There is no difference in the long- and short-term mortality and clinical outcomes between intraoperative use of volatile anesthetics and TIVA during CABG. However, volatile anesthetics may shorten the mechanical ventilation time. There is a need for high-quality multicenter RCTs that specifically assess factors that influence mortality and clinical outcomes.
目前仍不清楚在冠状动脉旁路移植术(CABG)患者中术中使用挥发性麻醉剂是否对术后临床结局有积极影响。因此,我们旨在系统分析与全凭静脉麻醉(TIVA)相比,挥发性麻醉剂在 CABG 患者中的长期和短期死亡率以及临床结局。
我们从 MEDLINE、Embase 和 CENTRAL 数据库中检索了从开始到 2019 年 10 月的关于 CABG 患者术中使用挥发性麻醉剂的相关随机对照试验(RCT)。
我们汇总并分析了 36 项符合条件的 RCT,共纳入 10308 例患者,发现 CABG 期间使用挥发性麻醉剂与 TIVA 之间在长期和短期死亡率方面没有显著差异。30 天死亡率,挥发性组(39/2824,1.4%)vs.TIVA 组(35/2786,1.3%),RR=1.11,95%CI[0.70,1.74],P 值=0.66,I=0%,中等确定性证据;1 年死亡率,挥发性组(77/2749,2.8%)vs.TIVA 组(78/2731,2.9%),RR=0.98,95%CI[0.72,1.34],P 值=0.90,I=0%,中等确定性证据。挥发性组机械通气时间缩短(MD-0.65,95%CI[-1.07,-0.24],P 值=0.002,I=26%)。
在 CABG 期间,术中使用挥发性麻醉剂与 TIVA 在长期和短期死亡率及临床结局方面没有差异。然而,挥发性麻醉剂可能会缩短机械通气时间。需要高质量的多中心 RCT 来专门评估影响死亡率和临床结局的因素。